PHILADELPHIA — Researchers at the Perelman School of Medicine at the University of Pennsylvania report in a new study that thickening of the heart’s right ventricle is associated with an increased risk of heart failure and cardiovascular death in patients without clinical cardiovascular disease at baseline. The study is published online ahead of print in the journal Circulation.
“In most studies of the heart, researchers have focused on the more-easily-imaged left ventricle, the region of the heart affected by systemic high blood pressure and other common conditions,” said study author Steven Kawut, M.D., M.S., associate professor of Medicine and Epidemiology and director of the Pulmonary Vascular Disease Program at Penn. “But we know from the results of this study and previous work that focusing attention on the right ventricle (RV) is critical in our understanding of many conditions of the heart and lungs. This research revealed that approximately one in 10 heart failure events and cardiovascular deaths may be attributed to thickening of the RV in adults without clinical cardiovascular disease at baseline.”
The researchers examined cardiac magnetic resonance (CMR) images of the right ventricles of 4,144 men and women, average age 61, participating in the Multi-Ethnic Study of Atherosclerosis (MESA). The MESA is a multicenter research project tracking the development of cardiovascular disease in 6,814 Caucasians, African-Americans, Hispanics and Chinese-Americans who did not have clinically-diagnosed heart disease at the beginning of the study.
Participants with RV hypertrophy (or abnormal thickening of the RV) had double the risk of heart failure or death compared to those with normal RV size. This association persisted after adjustment for age, sex, race/ethnicity, body mass index, education, smoking status, and other clinical indicators. This relationship was strongest in those with average or lower left ventricular mass.
“These findings run counter to the traditional belief that for otherwise-healthy adults, the RV plays a limited role in clinical heart failure,” said Kawut, who is also a member of the Penn Cardiovascular Institute. “The strong association our study found warrants further studies of the role of the RV in contributing to the risk of adverse outcomes. The MESA has repeated CMR images in these same participants ten years later, so our next goals are to understand the changes in the RV over time and how this tracks with how adults feel, function, and survive.”
This work was funded by several National Institutes of Health grants and contracts including R01-HL086719, R01-HL077612, K24- HL103844, and N01-HC95159 through N01-HC95169.
Penn Medicine is one of the world’s leading academic medical centers, dedicated to the related missions of medical education, biomedical research, excellence in patient care, and community service. The organization consists of the University of Pennsylvania Health System and Penn’s Raymond and Ruth Perelman School of Medicine, founded in 1765 as the nation’s first medical school.
The Perelman School of Medicine is consistently among the nation's top recipients of funding from the National Institutes of Health, with $550 million awarded in the 2022 fiscal year. Home to a proud history of “firsts” in medicine, Penn Medicine teams have pioneered discoveries and innovations that have shaped modern medicine, including recent breakthroughs such as CAR T cell therapy for cancer and the mRNA technology used in COVID-19 vaccines.
The University of Pennsylvania Health System’s patient care facilities stretch from the Susquehanna River in Pennsylvania to the New Jersey shore. These include the Hospital of the University of Pennsylvania, Penn Presbyterian Medical Center, Chester County Hospital, Lancaster General Health, Penn Medicine Princeton Health, and Pennsylvania Hospital—the nation’s first hospital, founded in 1751. Additional facilities and enterprises include Good Shepherd Penn Partners, Penn Medicine at Home, Lancaster Behavioral Health Hospital, and Princeton House Behavioral Health, among others.
Penn Medicine is an $11.1 billion enterprise powered by more than 49,000 talented faculty and staff.